We are pleased to announce the launch of Oxford Cancer Biomarkers’ newly designed website www.oxfordbio.com.
In redesigning our site, our goal is to provide a user-friendly browsing experience, in which to learn about our pioneering cancer biomarker technologies. We will continually update our content with helpful information, articles, blogs, company announcements and new products, so be sure to check back regularly.
We are active on social media and would be delighted if you would join us on our social media channels. The new website site contains integrated social media buttons for our Facebook, Twitter, and Linkedin accounts where we will keep you updated on our latest news.
Oxford Cancer Biomarkers is developing a range of predictive biomarkers that will help clinicians deliver personalised care to patients with colorectal cancer. The first to be launched is ToxNav, a 21 SNP germline assay that predicts individuals’ propensity to develop life-threatening adverse reactions from 5FU/capecitabine chemotherapy. ColoProg; a digital pathology test for the recurrence of Stage II tumours is already available in China. The company is working with academic partners to develop a population-based genome test for the lifetime risk of developing colorectal cancer. Oxford Cancer Biomarkers is closely affiliated with The University of Oxford, where its founders lead research groups focused on translational cancer science.